Compare BridgeBio Pharma Inc (BBIO) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs McDonald's Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while McDonald's Corp trades at $273.72 (market cap $193.70B). The key difference: McDonald's Corp is far larger — about 11.7× BridgeBio Pharma Inc's market cap, and McDonald's Corp pays a 2.72% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MCD | |
|---|---|---|
Market Cap | $16.61B | $193.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $341.06 |
52-Week Low | $47.29 | $262.80 |
Enterprise Value | $18.16B | $247.47B |
Volume | — | 2,230,036 |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
McDonald's (MCD) trades at $274.48, down 0.64% for the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $3.41. Revenue grew to $26.89 billion in 2025, supported by a net income margin of 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and customer experience improvements.
The outlook remains positive with a consensus price target of $322.45, implying significant upside. Strong fundamentals and analyst buy ratings (59.68%) support growth, though risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a solid dividend yield with recent payouts of $1.86 per share.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
